Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -15.82% is 61% above its 5-year average of -40.11%, near the high end of its 5-year range (-90.08%–-4.05%).
18.34% above its 12-month average of -19.37%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -17.39%.
NET PROFIT MARGIN
-15.82%
NET PROFIT MARGIN AVG TTM
-19.37%
NET PROFIT MARGIN AVG 3Y
-40.31%
NET PROFIT MARGIN AVG 5Y
-40.11%
NET PROFIT MARGIN AVG 10Y
-42.27%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.34%
CURRENT VS 3Y AVG
+60.76%
CURRENT VS 5Y AVG
+60.56%
CURRENT VS 10Y AVG
+62.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-5984.62%
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Net Profit Margin
-15.82%
TTM Avg
-19.37%
3Y Avg
-40.31%
5Y Avg
-40.11%
Market Cap
$1.94B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.89B
Net Profit Margin
-418.24%
TTM Avg
540.96%
3Y Avg
-464.63%
5Y Avg
-309.76%
Market Cap
$1.95B
Net Profit Margin
-13.36%
TTM Avg
-6.14%
3Y Avg
-11.71%
5Y Avg
-14.87%
Market Cap
$1.89B
Net Profit Margin
-404.00%
TTM Avg
-118.68%
3Y Avg
-90.84%
5Y Avg
-270.15%
Market Cap
$1.96B
Net Profit Margin
-83.00%
TTM Avg
-671.13%
3Y Avg
-506.01%
5Y Avg
-403.32%
Market Cap
$1.89B
Net Profit Margin
49.06%
TTM Avg
-18.57%
3Y Avg
-80.13%
5Y Avg
-53.74%
Market Cap
$1.97B
Net Profit Margin
15.03%
TTM Avg
11.31%
3Y Avg
2.06%
5Y Avg
-9.89%
Market Cap
$1.87B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | -15.82% | -19.37% | -40.31% | -40.11% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | 0.00% | 0.00% | 0.00% | 0.00% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | -418.24% | 540.96% | -464.63% | -309.76% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | -13.36% | -6.14% | -11.71% | -14.87% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -404.00% | -118.68% | -90.84% | -270.15% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | -83.00% | -671.13% | -506.01% | -403.32% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 49.06% | -18.57% | -80.13% | -53.74% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 15.03% | 11.31% | 2.06% | -9.89% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | 0.00% | 0.00% | 0.00% | 0.00% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | -3.18% | -24.20% | -10.68% | -8.90% |
Operating Margin
-18.5%
Net Profit Margin
-15.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -17.39% |
| 2026-03-31 | -22.35% |
| 2025-12-31 | -4.05% |
| 2025-09-30 | -20.72% |
| 2025-06-30 | -32.35% |
| 2025-03-31 | -50.05% |
| 2024-12-31 | -77.57% |
| 2024-09-30 | -41.47% |
| 2024-06-30 | -38.94% |
| 2024-03-31 | -43.59% |
| 2023-12-31 | -65.09% |
| 2023-09-30 | -76.02% |
| 2023-06-30 | -34.48% |
| 2023-03-31 | -25.67% |
| 2022-12-31 | -30.95% |
| 2022-09-30 | -48.65% |
| 2022-06-30 | -90.08% |
| 2022-03-31 | -15.43% |
| 2021-12-31 | -40.19% |
| 2021-09-30 | -50.55% |
| 2021-06-30 | -16.63% |
| 2021-03-31 | -22.90% |
| 2020-12-31 | -20.93% |
| 2020-09-30 | -18.66% |
| 2020-06-30 | -99.97% |
| 2020-03-31 | -72.54% |
| 2019-12-31 | -22.91% |
| 2019-09-30 | -55.89% |
| 2019-06-30 | -41.69% |
| 2019-03-31 | -51.88% |
| 2018-12-31 | -64.12% |
| 2018-09-30 | 8.02% |
| 2018-06-30 | -39.10% |
| 2018-03-31 | -44.07% |
| 2017-12-31 | -60.39% |
| 2017-09-30 | -145.74% |
| 2017-06-30 | -140.15% |
| 2017-03-31 | -72.25% |
